RESEARCH AGREEMENTResearch Agreement • May 16th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS RESEARCH AGREEMENT (this “Agreement”), dated as of September 15th, 2015 (the “Effective Date”), between Fortress Biotech, Inc. (f/k/a Coronado Biosciences, Inc.), a Delaware Corporation (the “Company”) having an address 3 Columbus Circle, 15th Floor, New York, NY 10019, and NeuPharma, Inc., a Delaware corporation (“NeuPharma”) having an address of 1175 Chess Drive, Ste 206, Foster City, CA 94404.
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • May 16th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations
THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (“Assignment and Assumption Agreement”) is effective as of September 15 2015, by and between by and between Fortress Biotech., Inc., a Delaware corporation (“Fortress”) and Checkpoint Therapeutics, Inc., a Delaware corporation (“Checkpoint”).
OPTION AGREEMENTOption Agreement • May 16th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
This Option Agreement (the “Agreement”) dated as of March 17, 2015 (the “Effective Date”), is entered into by and between Fortress Biotech, Inc. (“Fortress”), a Delaware Corporation having a place of business at 3 Columbus Circle, 15th Floor, New York, NY 10019, and TG Therapeutics, Inc. (“TG”), a Delaware Corporation having a place of business at 3 Columbus Circle, 15th Floor, New York, NY 10019, with respect to the following:
LICENSE AGREEMENTLicense Agreement • May 16th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”) is dated as of March 2, 2015 (the “Effective Date”) by and between Checkpoint Therapeutics, Inc., a Delaware corporation organized having its place of business at 3 Columbus Circle, New York, NY 10019 (“CTI”), and Dana-Farber Cancer Institute, Inc. located at 450 Brookline Ave., Boston, MA 02115 (“DFCI”). CTI, on the one hand, and DFCI, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • May 16th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations
THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (“Assignment and Assumption Agreement”) is effective December 18, 2015 (the “Effective Date”), by and between Fortress Biotech, Inc. (“Fortress”), a Delaware corporation, and Checkpoint Therapeutics, Inc. (“Checkpoint”), a Delaware corporation.
LICENSE AGREEMENT FOR CEP-9722License Agreement • May 16th, 2016 • Checkpoint Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is dated as of December 18, 2015 (the “Effective Date”) by and between Fortress Biotech, Inc., a Delaware corporation organized having its place of business at 3 Columbus Circle, New York, NY 10019 (“FBIO”), and Cephalon, Inc. a Delaware corporation having its place of business at 41 Moores Road, Frazier, PA 19355 (“Cephalon”). FBIO, on the one hand, and Cephalon, on the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”
